TAVNEOS, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)2

TAVNEOS should be initiated and monitored by healthcare professionals experienced in the diagnosis and treatment of GPA or MPA2

TAVNEOS-based regimen

Efficacy

achieved non-inferior clinical remission at Week 26 and superior sustained clinical remission at Week 52 vs a
GC-based regimen1*

EFFICACY
Efficacy

SECONDARY ENDPOINT
resulted in a lower absolute risk of relapse vs a GC-based regimen over 52 weeks1

EFFICACY
Efficacy

SECONDARY ENDPOINT
demonstrated sustained improvement in renal function over 1 year vs a GC-based regimen1

RENAL FUNCTION
Efficacy

SECONDARY ENDPOINT
allowed physicians to reduce GC use with a significant reduction in GC toxicity vs a GC-based regimen1,5

GC TOXICITY
Efficacy

includes TAVNEOS taken as a fixed oral dose 2

SAFETY & DOSING
Efficacy

TAVNEOS demonstrated a favourable safety profile1

SAFETY & DOSING
Efficacy

TAVNEOS is the first targeted treatment for AAV recognised by EULAR and KDIGO3,4,6,7

INNOVATIVE MOA

Introducing TAVNEOS: a first-in-class targeted treatment for GPA/MPA

Discover how to use TAVNEOS

*Clinical remission in the ADVOCATE study was defined as BVAS 0 and no GC use in previous 4 weeks.1

†TAVNEOS is administered as a fixed-dose regimen, and it is not necessary to monitor organ impairment and undertake additional analysis beyond what is needed for standard disease management. Hepatic enzymes, total bilirubin and white blood cell count must be monitored.2 Please consult the Summary of Product Characteristics for further information.

AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; EULAR, European Alliance of Associations for Rheumatology; GC, glucocorticoid; GPA, granulomatosis with polyangiitis; MOA, mechanism of action; MPA, microscopic polyangiitis.

1. Jayne D, et al. N Engl J Med 2021;384(7):599–609. 2. TAVNEOS EU SmPC July 2024. 3. Bekker P, et al. PLoS One 2016;11(10):e0164646. 4. European Medicine Agency (2021). First-in-class medicine recommended for treatment of rare blood vessel inflammation. Available at: https://www.ema.europa.eu/en/news/first-class-medicine-recommended-treatment-rare-blood-vessel-inflammation. Date accessed: July 2024. 5. Stone J, et al. Semin Arthritis Rheum 2022;55:152010. 6. Hellmich B, et al. Ann Rheum Dis 2023;0:1–18. 7. Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. Kidney Int 2024;105(3S):S71–S116.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.